539 related articles for article (PubMed ID: 29357090)
1. Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
Liu YC; Lee IC; Chen PY
J Neurooncol; 2018 May; 137(3):511-522. PubMed ID: 29357090
[TBL] [Abstract][Full Text] [Related]
2. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
William D; Walther M; Schneider B; Linnebacher M; Classen CF
PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
[TBL] [Abstract][Full Text] [Related]
4. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.
Musah-Eroje A; Watson S
J Neurooncol; 2019 Apr; 142(2):231-240. PubMed ID: 30694423
[TBL] [Abstract][Full Text] [Related]
5. Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
Ngo MT; Harley BAC
Biomaterials; 2019 Apr; 198():122-134. PubMed ID: 29941152
[TBL] [Abstract][Full Text] [Related]
6. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Beier D; Röhrl S; Pillai DR; Schwarz S; Kunz-Schughart LA; Leukel P; Proescholdt M; Brawanski A; Bogdahn U; Trampe-Kieslich A; Giebel B; Wischhusen J; Reifenberger G; Hau P; Beier CP
Cancer Res; 2008 Jul; 68(14):5706-15. PubMed ID: 18632623
[TBL] [Abstract][Full Text] [Related]
8. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
9. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
[TBL] [Abstract][Full Text] [Related]
10. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
11. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
12. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
13. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.
Dirkse A; Golebiewska A; Buder T; Nazarov PV; Muller A; Poovathingal S; Brons NHC; Leite S; Sauvageot N; Sarkisjan D; Seyfrid M; Fritah S; Stieber D; Michelucci A; Hertel F; Herold-Mende C; Azuaje F; Skupin A; Bjerkvig R; Deutsch A; Voss-Böhme A; Niclou SP
Nat Commun; 2019 Apr; 10(1):1787. PubMed ID: 30992437
[TBL] [Abstract][Full Text] [Related]
14. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
Beier D; Schulz JB; Beier CP
Mol Cancer; 2011 Oct; 10():128. PubMed ID: 21988793
[TBL] [Abstract][Full Text] [Related]
15. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma cell line shows phenotypes of cancer stem cells in hypoxic microenvironment of spheroids.
Ohnishi K; Tani T; Tojo N; Sagara JI
Biochem Biophys Res Commun; 2021 Mar; 546():150-154. PubMed ID: 33582558
[TBL] [Abstract][Full Text] [Related]
17. Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
Farace C; Oliver JA; Melguizo C; Alvarez P; Bandiera P; Rama AR; Malaguarnera G; Ortiz R; Madeddu R; Prados J
PLoS One; 2015; 10(7):e0134111. PubMed ID: 26230845
[TBL] [Abstract][Full Text] [Related]
18. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
19. Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Caylioglu D; Meyer RJ; Hellmold D; Kubelt C; Synowitz M; Held-Feindt J
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808494
[TBL] [Abstract][Full Text] [Related]
20. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.
Vora P; Seyfrid M; Venugopal C; Qazi MA; Salim S; Isserlin R; Subapanditha M; O'Farrell E; Mahendram S; Singh M; Bakhshinyan D; Chokshi C; McFarlane N; Dvorkin-Gheva A; Brown KR; Murty N; Moffat J; Bader GD; Singh SK
J Neurooncol; 2019 Jul; 143(3):417-428. PubMed ID: 31115870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
